<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004496.pub2" GROUP_ID="NEONATAL" ID="465103040413422970" MERGED_FROM="" MODIFIED="2012-06-06 10:54:30 -0400" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2&lt;/p&gt;&lt;p&gt;CL 4/04 (review)&lt;/p&gt;&lt;p&gt;&lt;br&gt;sent to Loni Mar 28/07&lt;/p&gt;&lt;p&gt;CL 4/07 (minor update)&lt;/p&gt;" NOTES_MODIFIED="2012-06-06 10:54:30 -0400" NOTES_MODIFIED_BY="Diane Haughton" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.2">
<COVER_SHEET MODIFIED="2012-06-06 10:29:00 -0400" MODIFIED_BY="Diane Haughton">
<TITLE>Intraventricular antibiotics for bacterial meningitis in neonates</TITLE>
<CONTACT>
<PERSON ID="15314" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sachin</FIRST_NAME>
<MIDDLE_INITIALS>S</MIDDLE_INITIALS>
<LAST_NAME>Shah</LAST_NAME>
<SUFFIX>MBBS, MD, DM</SUFFIX>
<POSITION>Director</POSITION>
<EMAIL_1>sshahdoc@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neonatal and Pediatric Intensive Care Services</DEPARTMENT>
<ORGANISATION>Aditya Birla Memorial Hospital</ORGANISATION>
<ADDRESS_1>Office no. 2, Arihant Building</ADDRESS_1>
<ADDRESS_2>39/32 Karve Road</ADDRESS_2>
<CITY>Pune</CITY>
<ZIP>411004</ZIP>
<REGION/>
<COUNTRY CODE="IN">India</COUNTRY>
<PHONE_1>91 20 30717644</PHONE_1>
<PHONE_2/>
<FAX_1>91 20 27277003</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-06-06 10:29:00 -0400" MODIFIED_BY="Diane Haughton">
<PERSON ID="15314" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sachin</FIRST_NAME>
<MIDDLE_INITIALS>S</MIDDLE_INITIALS>
<LAST_NAME>Shah</LAST_NAME>
<SUFFIX>MBBS, MD, DM</SUFFIX>
<POSITION>Director</POSITION>
<EMAIL_1>sshahdoc@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neonatal and Pediatric Intensive Care Services</DEPARTMENT>
<ORGANISATION>Aditya Birla Memorial Hospital</ORGANISATION>
<ADDRESS_1>Office no. 2, Arihant Building</ADDRESS_1>
<ADDRESS_2>39/32 Karve Road</ADDRESS_2>
<CITY>Pune</CITY>
<ZIP>411004</ZIP>
<REGION/>
<COUNTRY CODE="IN">India</COUNTRY>
<PHONE_1>91 20 30717644</PHONE_1>
<PHONE_2/>
<FAX_1>91 20 27277003</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8350" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Arne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ohlsson</LAST_NAME>
<SUFFIX/>
<POSITION>Professor Emeritus</POSITION>
<EMAIL_1>aohlsson@mtsinai.on.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Departments of Paediatrics, Obstetrics and Gynaecology and Institute of Health Policy, Management and Evaluation</DEPARTMENT>
<ORGANISATION>University of Toronto</ORGANISATION>
<ADDRESS_1>600 University Avenue</ADDRESS_1>
<ADDRESS_2/>
<CITY>Toronto</CITY>
<ZIP>M5G 1X5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15313" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Vibhuti</FIRST_NAME>
<MIDDLE_INITIALS>S</MIDDLE_INITIALS>
<LAST_NAME>Shah</LAST_NAME>
<SUFFIX/>
<POSITION>Staff Neonatologist, Mount Sinai Hospital</POSITION>
<EMAIL_1>vshah@mtsinai.on.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Associate Professor, Department of Paediatrics and Institute of Health Policy, Management and Evaluation</DEPARTMENT>
<ORGANISATION>University of Toronto</ORGANISATION>
<ADDRESS_1>600 University Avenue</ADDRESS_1>
<ADDRESS_2/>
<CITY>Toronto</CITY>
<ZIP>M5G 1X5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>416 586 4816</PHONE_1>
<PHONE_2>416 664 6708</PHONE_2>
<FAX_1>416 586 8745</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2011-06-09 10:36:24 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 04/07/07&lt;/p&gt;&lt;p&gt;New studies sought but none found: 04/07/07&lt;/p&gt;" NOTES_MODIFIED="2011-06-09 10:36:24 -0400" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="9" MONTH="6" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="5" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="17" MONTH="5" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2012-06-04 12:21:12 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-06-04 12:21:12 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="6" YEAR="2011"/>
<DESCRIPTION>
<P>Updated search found no new trials. One retrospective study of interest for this review was identified and has been included (<LINK REF="REF-Arnell-2007" TYPE="REFERENCE">Arnell 2007</LINK>).</P>
<P>No changes to conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-06-04 12:21:07 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="6" YEAR="2011"/>
<DESCRIPTION>
<P>This review updates the existing review "Intraventricular antibiotics for bacterial meningitis in neonates" published in the Cochrane Database of Systematic Reviews.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-06-09 10:36:27 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-06-09 10:36:27 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-10 09:54:46 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="7" YEAR="2007"/>
<DESCRIPTION>
<P>This review updates the review "Intraventricular antibiotics for bacterial meningitis in neonates" published in The Cochrane Library, Issue 4, 2004 (<LINK REF="REF-Shah-2004" TYPE="REFERENCE">Shah 2004</LINK>).<BR/>
<BR/>A repeat search of the literature was conducted on June 21, 2007. No new trials were identified.<BR/>
<BR/>The conclusions remain the same.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="17" MONTH="6" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-04-23 09:30:38 -0400" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Paediatrics, Mount Sinai Hospital, Toronto, Ontario</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2012-04-23 09:30:38 -0400" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-04-23 09:30:38 -0400" MODIFIED_BY="[Empty name]">
<NAME>Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN275201100016C</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-06-06 10:54:30 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-06-10 09:48:52 -0400" MODIFIED_BY="[Empty name]">Intraventricular antibiotics for bacterial meningitis in neonates</TITLE>
<SUMMARY_BODY MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<P>Infection of the membranes and the fluid surrounding the brain (meningitis) and of the fluid-filled spaces in the brain (ventriculitis) may be caused by bacteria, especially gram-negative bacteria. This type of infection is difficult to eradicate using safe doses of antibiotics given into the blood stream. In theory, intraventricular administration of antibiotics (administration of antibiotics into the fluid-filled spaces in the centre of the brain) would produce higher antibiotic concentrations in the fluid in the brain than intravenous administration alone, and eliminate the bacteria more quickly. However, taps of the fluid-filled spaces may cause harm as the needle has to penetrate the brain tissue. Only one trial was identified. In this trial enrolling infants with gram-negative meningitis and ventriculitis, the use of intraventricular antibiotics in addition to intravenous antibiotics resulted in a three-fold increased risk for mortality compared to standard treatment with intravenous antibiotics alone. Based on this result, intraventricular antibiotics should be avoided. Further trials comparing these interventions are not justified in newborn infants.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Neonatal meningitis may be caused by bacteria, especially gram-negative bacteria, which are difficult to eradicate from the cerebrospinal fluid (CSF) using safe doses of antibiotics. In theory, intraventricular administration of antibiotics would produce higher antibiotic concentrations in the CSF than intravenous administration alone, and eliminate the bacteria more quickly. However, ventricular taps may cause harm.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effectiveness and safety of intraventricular antibiotics (with or without intravenous antibiotics) in neonates with meningitis (with or without ventriculitis) as compared to treatment with intravenous antibiotics alone.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-05-28 12:36:38 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>The Cochrane Library</I>, Issue 2, 2007; MEDLINE; EMBASE; CINAHL and Science Citation Index were searched in June 2007. The Oxford Database of Perinatal Trials was searched in June 2004. Pediatric Research (abstracts of proceedings) were searched (1990 to April 2007) as were reference lists of identified trials and personal files. No language restrictions were applied.</P>
<P>This search was updated in May 2011.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-05-28 12:36:48 -0400" MODIFIED_BY="[Empty name]">
<P>Selection criteria for study inclusion were: randomised or quasi-randomised controlled trials in which intraventricular antibiotics with or without intravenous antibiotics were compared with intravenous antibiotics alone in neonates (&lt; 28 days old) with meningitis. One of the following outcomes was required to be reported: mortality during initial hospitalisation; neonatal or infant mortality, or both; neurodevelopmental outcome; duration of hospitalisation; duration of culture positivity of CSF and side effects.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-05-28 12:37:01 -0400" MODIFIED_BY="[Empty name]">
<P>All review authors abstracted information for outcomes reported and one review author checked for discrepancies and entered data into RevMan 5.1. Risk ratio (RR), risk difference (RD), number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful outcome (NNTH), and mean difference (MD), using the fixed-effect model are reported with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-05-28 12:37:18 -0400" MODIFIED_BY="[Empty name]">
<P>The updated search in June 2011 did not identify any new trials. One study is included in the review. This study assessed the effect of intraventricular gentamicin in a mixed population of neonates (69%) and older infants (31%) with gram-negative meningitis and ventriculitis. Mortality was statistically significantly higher in the group that received intraventricular gentamicin in addition to intravenous antibiotics compared to the group receiving intravenous antibiotics alone (RR 3.43; 95% CI 1.09 to 10.74; RD 0.30; 95% CI 0.08 to 0.53); NNTH 3; 95% CI 2 to 13). Duration of CSF culture positivity did not differ significantly (MD -1.20 days; 95% CI -2.67 to 0.27).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<P>In one trial that enrolled infants with gram-negative meningitis and ventriculitis, the use of intraventricular antibiotics in addition to intravenous antibiotics resulted in a three-fold increased RR for mortality compared to standard treatment with intravenous antibiotics alone. Based on this result, intraventricular antibiotics as tested in this trial should be avoided. Further trials comparing these interventions are not justified in this population.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<P>Bacterial meningitis is more common in the first month of life than at any other age (<LINK REF="REF-Pong-1999" TYPE="REFERENCE">Pong 1999</LINK>). The epidemiology of meningitis in the neonatal period is similar to that of neonatal sepsis. Meningitis can occur as a part of sepsis in both the early and late-onset time periods or as focal infection as late-onset disease (<LINK REF="REF-Pong-1999" TYPE="REFERENCE">Pong 1999</LINK>; <LINK REF="REF-Klein-2000" TYPE="REFERENCE">Klein 2000</LINK>). The incidence of neonatal bacterial meningitis ranges from 0.25 per 1000 live births to 1 per 1000 live births (<LINK REF="REF-Bell-1989" TYPE="REFERENCE">Bell 1989</LINK>; <LINK REF="REF-Hristeva-1993" TYPE="REFERENCE">Hristeva 1993</LINK>). Meningitis occurs in approximately 25% of neonates with bacteraemia (<LINK REF="REF-Klein-2000" TYPE="REFERENCE">Klein 2000</LINK>). The risk factors for meningitis include preterm birth, maternal chorioamnionitis, prolonged pre-labour rupture of foetal membranes and presence of a foreign body such as a cerebrospinal fluid (CSF) shunt (<LINK REF="REF-Ronan-1995" TYPE="REFERENCE">Ronan 1995</LINK>; <LINK REF="REF-Klein-2000" TYPE="REFERENCE">Klein 2000</LINK>).</P>
<P>Group B &#946;-haemolytic streptococci (GBS), gram-negative enteric bacteria and <I>Listeria monocytogenes</I> are the most common agents causing meningitis (<LINK REF="REF-Pong-1999" TYPE="REFERENCE">Pong 1999</LINK>). Infection with gram-negative bacilli accounts for 30% to 40% of cases of meningitis (<LINK REF="REF-Dawson-1999" TYPE="REFERENCE">Dawson 1999</LINK>), with <I>Escherichia coli</I> (<I>E. coli</I>) being the most common organism isolated (50% of all gram-negative isolates) (<LINK REF="REF-Anderson-1990" TYPE="REFERENCE">Anderson 1990</LINK>; Unhanand 1993; <LINK REF="REF-Dawson-1999" TYPE="REFERENCE">Dawson 1999</LINK>) followed by <I>Klebsiella</I> species (<LINK REF="REF-Klein-2000" TYPE="REFERENCE">Klein 2000</LINK>). Other organisms that have been implicated to cause meningitis include enterobacter, citrobacter and serratia species (<LINK REF="REF-Polin-2001" TYPE="REFERENCE">Polin 2001</LINK>). Meningitis with organisms such as coagulase-negative staphylococcus and pseudomonas species (<LINK REF="REF-Polin-2001" TYPE="REFERENCE">Polin 2001</LINK>) is more common in neonates requiring prolonged hospitalisation, need for central venous catheters, parenteral nutrition and ventilatory support.</P>
</CONDITION>
<INTERVENTION MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<P>Prior to the availability of antibiotics, bacterial meningitis was a uniformly fatal disease (<LINK REF="REF-Flexner-1913" TYPE="REFERENCE">Flexner 1913</LINK>; <LINK REF="REF-Scheld-1984" TYPE="REFERENCE">Scheld 1984</LINK>). The development of modern methods of intensive care and newer antibiotics resulted in decline in mortality to 10% to 25% in infancy (<LINK REF="REF-Dawson-1999" TYPE="REFERENCE">Dawson 1999</LINK>; <LINK REF="REF-Harvey-1999" TYPE="REFERENCE">Harvey 1999</LINK>; <LINK REF="REF-Heath-2003" TYPE="REFERENCE">Heath 2003</LINK>). However, the incidence of neurological morbidity in infants who survive bacterial meningitis is high, ranging from 20% to 80%, and is somewhat dependent on the infecting organism (<LINK REF="REF-Harvey-1999" TYPE="REFERENCE">Harvey 1999</LINK>; <LINK REF="REF-Klinger-2000" TYPE="REFERENCE">Klinger 2000</LINK>; <LINK REF="REF-Heath-2003" TYPE="REFERENCE">Heath 2003</LINK>). Acute complications of meningitis include death, seizures, ventriculitis, hydrocephalus, subdural effusion and brain abscess (<LINK REF="REF-Baumgartner-1983" TYPE="REFERENCE">Baumgartner 1983</LINK>; <LINK REF="REF-Hristeva-1993" TYPE="REFERENCE">Hristeva 1993</LINK>). The disease is often more severe with gram-negative bacteria than gram-positive bacteria, with higher rates of both mortality and morbidity (<LINK REF="REF-Franco-1992" TYPE="REFERENCE">Franco 1992</LINK>). Gram-negative meningitis results in prolonged duration of CSF bacterial culture positivity compared to GBS. A delay in achieving CSF sterilisation has been shown to be associated with increased neurological sequelae (<LINK REF="REF-McCracken-1972" TYPE="REFERENCE">McCracken 1972</LINK>; <LINK REF="REF-Unhanand--1993" TYPE="REFERENCE">Unhanand 1993</LINK>). Long-term sequelae among survivors of meningitis include hydrocephalus, developmental delay, cerebral palsy, seizures requiring anticonvulsant therapy, decreased visual acuity and hearing loss (<LINK REF="REF-Baumgartner-1983" TYPE="REFERENCE">Baumgartner 1983</LINK>; <LINK REF="REF-Hristeva-1993" TYPE="REFERENCE">Hristeva 1993</LINK>).</P>
<P>For these reasons, antibiotic therapy for meningitis should be aggressive. The doses used must achieve a bactericidal concentration of antibiotic in the CSF. The standard therapy for neonatal meningitis is intravenous administration of antibiotics. Efficient elimination of bacteria depends not only on the ability of an antibiotic to enter the CSF, but also on the relationship between the concentration of antibiotic in the CSF and the minimal bactericidal concentration (MBC) for the infecting pathogen. Therefore, while gentamicin can enter CSF relatively readily (CSF/serum concentration 20% to 25%), the concentrations achieved in CSF are close to the MBC only for susceptible organisms (<LINK REF="REF-McCracken-1982" TYPE="REFERENCE">McCracken 1982</LINK>; <LINK REF="REF-Polin-2001" TYPE="REFERENCE">Polin 2001</LINK>). In contrast, &#946;-lactam antibiotics such as penicillins or cephalosporins enter CSF less readily, but because larger doses can be used without toxicity, the concentrations achieved are far higher than the MBC (<LINK REF="REF-Polin-2001" TYPE="REFERENCE">Polin 2001</LINK>). Since CSF drug concentrations can lag behind serum drug levels, a single measurement may underestimate the true ability of a drug to enter the CSF. The more reliable estimate is the area under concentration curve, but that requires multiple CSF samples and cannot be routinely done in humans (<LINK REF="REF-Polin-2001" TYPE="REFERENCE">Polin 2001</LINK>).</P>
<P>The initial choice of intravenous antibiotics for neonates with suspected meningitis must cover both gram-positive and gram-negative organisms (<LINK REF="REF-Quagliarello-1997" TYPE="REFERENCE">Quagliarello 1997</LINK>). Therefore, empiric therapy generally includes ampicillin in addition to either an aminoglycoside or a third-generation cephalosporin. Once a pathogen has been isolated, antibiotic therapy for bacterial meningitis can be tailored to the pathogen.<BR/>
</P>
</INTERVENTION>
<THEORY MODIFIED="2012-05-28 12:38:41 -0400" MODIFIED_BY="[Empty name]">
<P>In theory, the intraventricular route of administration of antibiotics would achieve higher antibiotic concentrations in the CSF and eliminate the bacteria more quickly. In a prospective study of 16 infants with neonatal meningitis, Lee and co-workers (<LINK REF="REF-Lee-1977" TYPE="REFERENCE">Lee 1977</LINK>) used a combination of systemic and intraventricular antibiotics. Fifteen infants survived the infection and, of these infants, seven were normal on follow-up. There were no acute adverse reactions after the use of intraventricular antibiotics. A retrospective review of gram-negative meningitis in neonates demonstrated that the mortality was lower after intraventricular plus systemic antibiotic therapy than after systemic antibiotic therapy alone (<LINK REF="REF-Wright-1981" TYPE="REFERENCE">Wright 1981</LINK>). The authors suggested that if careful attention is given to the pharmacokinetics of intraventricular therapy, this route may be a valuable adjunct to therapy for gram-negative meningitis. Techniques used for intraventricular drug administration in these trials included repeated ventricular taps, open or closed implanted catheter, or use of Omaya or Rickham reservoir. Intraventricular antibiotics have also been used in children with CSF shunt infection with variable results (<LINK REF="REF-James-1980" TYPE="REFERENCE">James 1980</LINK>; <LINK REF="REF-Stamos-1993" TYPE="REFERENCE">Stamos 1993</LINK>) and controversy exists as to the best treatment of shunt infections. Several therapeutic modalities are currently used for the treatment of shunt infections including: 1) intravenous antibiotics with/without intrashunt antibiotics with shunt removal and external ventricular drain or ventricular taps, 2) intravenous antibiotics with/without intrashunt antibiotics with shunt removal and immediate replacement and 3) intravenous antibiotics with/without intrashunt antibiotics without removal of the infected shunt (<LINK REF="REF-James-1980" TYPE="REFERENCE">James 1980</LINK>; <LINK REF="REF-Whitehead-2001" TYPE="REFERENCE">Whitehead 2001</LINK>).</P>
<P>Although we could not identify any new trials in 2011 for this update of our review, we did identify one retrospective study of interest to this review. <LINK REF="REF-Arnell-2007" TYPE="REFERENCE">Arnell 2007</LINK> reported on a retrospective study of the management of shunt infection in children. The authors followed a protocol that included a two-stage procedure involving externalisation of the ventricular catheter in combination with intraventricular and systemic administration of antibiotic medication followed by shunt replacement. Intraventricular treatment consisted of daily instillations of vancomycin or gentamicin with trough concentrations held at high levels of 7 to 17 mg/L for both antibiotic agents.</P>
<P>During a 13-year study period, the authors treated 34 consecutive intraventricular shunt infections in 30 children. Ten of the children were initially treated with intravenous antibiotic therapy for at least three days, but this treatment did not sterilise the CSF. After externalisation of the ventricular catheter, high-dose intraventricular treatment was given for a median of eight days (range three to 17 days) before shunt replacement.</P>
<P>The CSF was found to be sterile in one of three, seven of eight, 20 of 20, and six of six cases after one, two, three and more than three days' treatment, respectively. In no case was any subsequent culture positive after a negative result had been obtained. Clinical symptoms resolved in parallel with the sterilisation of the CSF. There were no relapses or deaths during the six-month follow-up period, and there have been none as of April 2007.</P>
<P>The study authors concluded that despite the ventricular catheter being left in place and the short duration of therapy, the treatment regimen described by the authors resulted in quick sterilisation of the CSF, a low relapse rate, and survival of all patients in this series.</P>
<P>However, a ventricular tap for the administration of antibiotics is an invasive procedure that is associated with its own risks. Repeated needle aspirations of ventricular fluid have been associated with development of porencephalic cysts (<LINK REF="REF-Salmon-1967" TYPE="REFERENCE">Salmon 1967</LINK>). In healthy adult rabbits, Watanabe and co-workers were consistently able to produce widespread axonal degeneration, myelin swelling and glia-cell necrosis after intracisternal inoculation of gentamicin (<LINK REF="REF-Watanabe-1978" TYPE="REFERENCE">Watanabe 1978</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2012-05-28 12:38:46 -0400" MODIFIED_BY="[Empty name]">
<P>Studies have been conducted in neonates with bacterial meningitis with the hypothesis that larger concentrations of drug resulting from direct inoculation into the CSF space would sterilise cultures more rapidly and improve outcome from the disease. This systematic review evaluates the evidence from those trials.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-05-28 12:39:13 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Primary objective</HEADING>
<P>To determine the effectiveness and safety of intraventricular antibiotics (with or without intravenous antibiotics) in neonates with meningitis (with or without ventriculitis) as compared to conventional treatment with intravenous antibiotics alone.</P>
<P>To assess the effectiveness and safety of intraventricular antibiotics, the following separate comparisons were planned:<BR/>
</P>
<UL>
<LI>intraventricular antibiotics alone vs. intravenous antibiotics alone,</LI>
<LI>intraventricular plus intravenous antibiotics vs. intravenous antibiotics alone,</LI>
<LI>infants with or without a CSF shunt (e.g. ventricular peritoneal shunt, ventriculostomy reservoir, etc.).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Secondary objectives</HEADING>
<P>To determine in subgroup analyses the effectiveness and safety of intraventricular antibiotics in relation to the following criteria:<BR/>
</P>
<UL>
<LI>gestational age (&lt; 37 weeks and &#8805; 37 weeks) or birth weight (&lt; 2500 g and &#8805; 2500 g),</LI>
<LI>presence or absence of documented ventriculitis,</LI>
<LI>type of infecting organism (gram-positive or gram-negative organisms),</LI>
<LI>type of antibiotic used (aminoglycosides, cephalosporins, etc.).</LI>
</UL>
</SUBSECTION>
</OBJECTIVES>
<METHODS MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2012-05-28 12:39:46 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised or quasi-randomised controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<P>Term or preterm (&lt; 37 weeks' gestational age) infants in the neonatal period (&lt; 28 days) with bacterial meningitis with or without ventriculitis.</P>
<P>The criteria for diagnosis of bacterial meningitis should include the following:</P>
<OL>
<LI>positive CSF culture or positive gram stain, or both.</LI>
</OL>
<P>The criteria for diagnosis of ventriculitis should include one of the following:</P>
<OL>
<LI>positive ventricular fluid culture;</LI>
<LI>leukocytosis (&gt; 50 cells/mm<SUP>3</SUP>) with/without organisms identified on gram staining.</LI>
</OL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>The intervention should be intraventricular administration of any antibiotic (of any duration) with or without intravenous antibiotic treatment compared with intravenous antibiotic treatment alone. <BR/>The antibiotic used for intraventricular administration may/may not be the one used for intravenous therapy.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<OL>
<LI>All-cause mortality during the hospital stay.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-05-28 12:40:21 -0400" MODIFIED_BY="[Empty name]">
<OL>
<LI>Neonatal mortality (death during the first 28 days of life).</LI>
<LI>Infant mortality (death during the first year of life).</LI>
<LI>Neurodevelopmental outcome (neurodevelopmental outcome assessed by a standardised and validated assessment tool or a child developmental specialist, or both) at any age (outcome data will be grouped at 12, 18 and 24 months if available).</LI>
<LI>Duration of hospitalisation (total length of hospitalisation from birth to discharge home or death).</LI>
<LI>Duration of culture positivity of CSF.</LI>
<LI>Antimicrobial side effects (diarrhoea, fungal infection, anaphylaxis etc.).</LI>
<LI>Any side effects not listed as an outcome above but reported by the study authors as a side effect.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<P>See: Cochrane Neonatal Review Group search strategy.</P>
<P>MEDLINE database (1966 to June 2007) was searched using MeSH terms: "infant, newborn" AND "meningitis" AND "intraventricular" AND "antibiotics" AND (random allocation OR controlled trial OR randomised controlled trial). The Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I>, Issue 2, 2007), EMBASE (1980 to June 2007) and CINAHL (1982 to June 2007), and abstracts (American Pediatric Society and European Society for Paediatric Research annual meetings) published in <I>Pediatric Research</I> (1990 to April 2007) were searched either manually or electronically in the PAS Abstract Archive (2000 to 2007). The reference lists of identified trials were searched to identify potential articles for inclusion. Science Citation Index was searched on the reference to the only trial found (<LINK REF="STD-McCracken-1980" TYPE="STUDY">McCracken 1980</LINK>). The Oxford Database of Perinatal Trials was searched for the initial review. Unpublished data were not sought, but authors of published trials were to be contacted to clarify or provide additional information. No language restrictions were applied. The retrieved articles were screened by the three review authors to identify articles eligible for inclusion in this review.</P>
<P>In May 2011, we updated the search. See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<P>We used the standard review methods of the Cochrane Neonatal Review Group.<BR/>All abstracts and published studies identified as potentially relevant by the literature search were assessed for inclusion in the review by the two review authors (SS, AO).</P>
<STUDY_SELECTION MODIFIED="2012-04-30 11:37:13 -0400" MODIFIED_BY="[Empty name]">
<P>We assessed all abstracts and published full reports identified as potentially relevant by the literature for inclusion in the review.<BR/>
</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<P>If studies were identified, each review author would extract data separately on a data abstraction form. The information would then be compared and differences would be resolved by consensus. One review author (AO) would enter data into RevMan 5.1 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>) and the other author (SS) would cross check the printout against his own data abstraction forms and errors would be corrected.</P>
<P>For the studies identified as abstracts, primary authors were to be contacted to ascertain whether a full publication was available if the full paper was not identified in an electronic data base. The primary author of the identified trial (<LINK REF="STD-McCracken-1980" TYPE="STUDY">McCracken 1980</LINK>) was contacted for additional information.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-05-28 12:43:48 -0400" MODIFIED_BY="[Empty name]">
<P>Quality assessments of the retrieved articles were conducted by the review authors, who were not blinded to authors, institution or journal of publication. The quality of included trials was evaluated independently by the review authors, using the following criteria:</P>
<P>Selection bias (random sequence generation and allocation concealment).</P>
<SUBSECTION>
<HEADING LEVEL="4">Adequate sequence generation?</HEADING>
<P>For each included study, we would categorise the risk of selection bias as:</P>
<UL>
<LI>low risk - adequate (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>high risk - inadequate (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);</LI>
<LI>unclear risk - no or unclear information provided.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment?</HEADING>
<P>For each included study, we would categorise the risk of bias regarding allocation concealment as:</P>
<UL>
<LI>low risk - adequate (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk - inadequate (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear risk - no or unclear information provided.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding?</HEADING>
<P>Performance bias: for each included study, we would categorise the methods used to blind study personnel from knowledge of which intervention a participant received (as our study population consisted of neonates they would all be blinded to the study intervention.):</P>
<UL>
<LI>low risk - adequate for personnel (a placebo that could not be distinguished from the active drug was used in the control group);</LI>
<LI>high risk - inadequate - personnel aware of group assignment;</LI>
<LI>unclear risk - no or unclear information provided.</LI>
</UL>
<P>Detection bias: for each included study, we would categorise the methods used to blind outcome assessors from knowledge of which intervention a participant received. (As our study population consisted of neonates they would all be blinded to the study intervention). Blinding would be assessed separately for different outcomes or classes of outcomes. We would categorise the methods used with regards to detection bias as:</P>
<UL>
<LI>low risk - adequate; follow-up was performed with assessors blinded to group;</LI>
<LI>high risk - inadequate; assessors at follow-up were aware of group assignment;</LI>
<LI>unclear risk - no or unclear information provided.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete data addressed?</HEADING>
<P>Attrition bias: for each included study and for each outcome, we would describe the completeness of data including attrition and exclusions from the analysis. We would note whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported or supplied by the trial authors, we would re-include missing data in the analyses. We would categorise the methods with respect to the risk of attrition bias as:</P>
<UL>
<LI>low risk - adequate (&lt; 10% missing data);</LI>
<LI>high risk - inadequate (&gt; 10% missing data);</LI>
<LI>unclear risk - no or unclear information provided.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Free of selective reporting?</HEADING>
<P>Reporting bias</P>
<P>For each included study, we would describe how we investigated the risk of selective outcome reporting bias and what we found. We would assess the methods as:</P>
<UL>
<LI>low risk - adequate (where it is clear that all of the study's pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>high risk - inadequate (where not all the study's pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear risk - no or unclear information provided (the study protocol was not available).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Free of other bias?</HEADING>
<P>Other bias: for each included study, we would describe any important concerns we had about other possible sources of bias (e.g. whether there was a potential source of bias related to the specific study design or whether the trial was stopped early due to some data-dependent process). We would assess whether each study was free of other problems that could put it at risk of bias as:</P>
<UL>
<LI>low risk - no concerns of other bias raised;</LI>
<LI>high risk - concerns raised about multiple looks at the data with the results made known to the investigators, difference in number of patients enrolled in abstract and final publications of the paper;</LI>
<LI>unclear - concerns raised about potential sources of bias that could not be verified by contacting the authors.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Overall risk of bias?</HEADING>
<P>We would make explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We would assess the likely magnitude and direction of the bias and whether we considered it was likely to impact on the findings. We would explore the impact of the level of bias through undertaking sensitivity analyses - see '<LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>'.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-05-28 12:44:06 -0400" MODIFIED_BY="[Empty name]">
<P>The statistical analyses followed the recommendations of the Cochrane Neonatal Review Group and were performed using the RevMan 5.1 software. The estimates of treatment effects included risk ratio (RR), risk difference (RD), number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful outcome (NNTH) for dichotomous outcomes, and weighted mean difference (WMD) (or mean difference (MD) if only one trial was included) for continuous outcomes. All estimates of treatment effects are reported with 95% confidence intervals (CI). A fixed-effect model was to be used for meta-analyses.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-04-24 09:41:03 -0400" MODIFIED_BY="[Empty name]">
<P>The unit of analysis would be the individual patient.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-04-24 09:40:06 -0400" MODIFIED_BY="[Empty name]">
<P>If we had identified trials with missing data, we would approach the authors to provide us with additional information.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-05-28 12:44:13 -0400" MODIFIED_BY="[Empty name]">
<P>Heterogeneity tests would be performed to assess the appropriateness of pooling the data. Results of the I<SUP>2</SUP> statistic would be reported.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-04-24 09:42:54 -0400" MODIFIED_BY="[Empty name]">
<P>If at least 10 trials were included in one meta-analysis we would perform a funnel plot. If there was asymmetry, we would try and explain it based on study characteristics.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-05-28 12:44:23 -0400" MODIFIED_BY="[Empty name]">
<P>We planned to perform statistical analyses according to the recommendations of the Cochrane Neonatal Review Group (<A HREF="http://neonatal.cochrane.org/en/index.html">neonatal.cochrane.org/en/index.html</A>). We planned to analyse all infants randomised on an intention-to-treat basis. We planned to analyse treatment effects in the individual trials. We planned to use a fixed-effect model for meta-analysis in the first instance to combine the data. Where substantial heterogeneity existed, the potential cause of heterogeneity would be examined in subgroup and sensitivity analyses. When we judged meta-analysis to be inappropriate, we planned to analyse and interpret individual trials separately. For estimates of typical RR and RD, we would use the Mantel-Haenszel method. For measured quantities, we would use the inverse variance method.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-05-28 12:44:38 -0400" MODIFIED_BY="[Empty name]">
<P>Planned subgroup analyses were to be performed according to the criteria listed under objectives.</P>
<P>To assess the effectiveness and safety of intraventricular antibiotics, the following separate comparisons were planned:<BR/>
</P>
<UL>
<LI>intraventricular antibiotics alone versus intravenous antibiotics alone;</LI>
<LI>intraventricular plus intravenous antibiotics versus intravenous antibiotics alone;</LI>
<LI>infants with or without a CSF shunt (e.g. ventricular peritoneal shunt, ventriculostomy reservoir, etc.).</LI>
</UL>
<P>Secondary objectives:<BR/>To determine in subgroup analyses the effectiveness and safety of intraventricular antibiotics in relation to the following criteria:<BR/>
</P>
<UL>
<LI>gestational age (&lt; 37 weeks and &#8805; 37 weeks) or birth weight (&lt; 2500 g and &#8805; 2500 g);</LI>
<LI>presence or absence of documented ventriculitis;</LI>
<LI>type of infecting organism (gram-positive or gram-negative organisms);</LI>
<LI>type of antibiotic used (aminoglycosides, cephalosporins, etc.).</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-04-24 09:42:44 -0400" MODIFIED_BY="[Empty name]">
<P>No sensitivity analyses were planned a priori, but could be conducted depending on the results.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<P>The literature search did not identify any study that strictly met all of the inclusion criteria either in June 2004 or in the updated searches in June 2007 and May 2011. However, one randomised controlled trial conducted in both neonates and infants was identified (<LINK REF="STD-McCracken-1980" TYPE="STUDY">McCracken 1980</LINK>). Outcomes specific to the different age groups could not be abstracted. The primary author was contacted and asked whether data for the infants &lt; 28 days could be provided. He responded that he no longer had the original data from that study. We chose to deviate from our protocol and included this study in this systematic review as 69% of the randomised infants with ventriculitis were less than 30 days old at the time of enrolment. The study was conducted in 20 institutions in the US and Latin America more than 25 years ago. The rationale for enrolling only infants with meningitis caused by gram-negative bacteria was based on the high mortality in this population and the longer duration of CSF positivity in meningitis caused by gram-negative bacteria compared to gram-positive bacteria. Higher concentrations of gentamicin for longer duration in intraventricular fluid following intraventricular injection had previously been found in adults, justifying this trial in infants. Eighty-seven infants were considered for enrolment in the study but 16 were found unacceptable (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for details). The remaining 71 infants had ventricular taps and lumbar punctures. Nineteen did not have ventriculitis and these infants were assigned to receive systemic antibiotics plus lumbar intrathecal gentamicin or systemic antibiotics only. The latter stratum was not included in this review as neither group received intraventricular antibiotics. Fifty-two infants with meningitis (caused by gram-negative enteric bacilli) and ventriculitis (diagnosed by &#8805; 50 white cells/mL ventricular fluid with or without gram-negative rods on stained smear or culture of ventricular fluid) were randomly allocated to receive either intraventricular antibiotics plus intravenous antibiotics or intravenous antibiotics alone. Only these 52 infants are included in this review. The most commonly isolated bacteria were <I>E coli</I> (38.5%), Klebsiella-enterobacter and citrobacter (28.8%), and Salmonella (19.2%). Other organisms were found in 13.5% of the infants. Outcomes that were reported included mortality during hospital stay, days of positive CSF cultures (obtained from intraventricular or lumbar CSF samples, or both) and morbidity on follow-up examinations.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-05-28 12:45:09 -0400" MODIFIED_BY="[Empty name]">
<P>In the included study (<LINK REF="STD-McCracken-1980" TYPE="STUDY">McCracken 1980</LINK>) the allocation of the study subjects to the two interventions was concealed. The researchers/health care providers could not be blinded to the interventions. It is unclear whether the outcome assessments, specifically the long-term assessments, were performed blinded to group assignment. Survivors were scheduled for follow-up evaluations six and 12 months after illness and yearly thereafter. Complete physical, neurological, and Denver developmental examinations were to be done at each visit. The Cattell infant intelligence and Gessell fine and gross motor developmental tests were administered to some infants aged 12 months or more. The study authors do not state the age of the infants/children at the time of their follow-up and the number of children who underwent which exam/test. No sample-size calculation or any pre-determined stopping rules were reported. The study was terminated early because of the higher mortality rate in the intraventricular-therapy group.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Intraventricular plus intravenous antibiotics versus intraventricular antibiotics alone (Comparison 1)</HEADING>
<P>
<BR/>One study (<LINK REF="STD-McCracken-1980" TYPE="STUDY">McCracken 1980</LINK>) was included for this comparison.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">All-cause mortality during hospital stay (Outcome 1.1)</HEADING>
<P>The mortality was statistically significantly higher in the group that received intraventricular antibiotics and intravenous antibiotics compared to the group that received intravenous antibiotics only (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The RR was 3.43 (95% CI 1.09 to 10.74); RD was 0.30 (95% CI 0.08 to 0.53) and NNTH was 3 (95% CI 2 to 13). In a secondary publication (<LINK REF="STD-McCracken-1980" TYPE="STUDY">McCracken 1980</LINK>), the same group reported increased endotoxin and interleukin-1&#946; concentrations in CSF of infants with coliform meningitis and ventriculitis associated with intraventricular gentamicin therapy. This subgroup of 21 patients, of which 10 received intraventricular plus intravenous antibiotics and 11 received intravenous antibiotics alone, were included in the original trial (<LINK REF="STD-McCracken-1980" TYPE="STUDY">McCracken 1980</LINK>). The authors proposed that intraventricular gentamicin may cause release of endotoxin from gram-negative bacilli in ventricular CSF, resulting in increased interleukin-1&#946; concentrations and inflammation, which could have contributed to the poor outcome in these patients.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Neonatal mortality (death during the first 28 days of life)</HEADING>
<P>Data for this outcome could not be abstracted.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Infant mortality (death during the first year of life)</HEADING>
<P>Data for this outcome could not be abstracted. Most deaths occurred within 14 days after the therapy was started. One infant/child died 36 days after the therapy was started from aspiration pneumonia and one from recurrence of meningitis 199 days following enrolment in the study. These deaths could have occurred beyond one year of age.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Neurodevelopmental outcome</HEADING>
<P>Neurodevelopmental outcome (assessed by a standardised and validated assessment tool or a child developmental specialist, or both) at any age (outcome data to be grouped at 12, 18 and 24 months if available.)</P>
<P>It is unclear how old the infants were when assessed for long-term morbidity. We contacted the primary author, but the research team no longer had the original data to make clarifications.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Duration of hospitalisation (total length of hospitalisation from birth to discharge home or death)</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Duration of culture positivity of CSF (Outcome 1.2)</HEADING>
<P>There was no statistically significant difference in the days of positive CSF cultures (ascertained by ventricular or lumbar CSF specimens, or both) (MD -1.20 days; 95% CI -2.67 to 0.27) with a trend favouring the intraventricular plus intravenous antibiotics group compared to the intravenous antibiotics only group (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Antimicrobial side effects (diarrhoea, fungal infection, anaphylaxis<I>,</I> etc.)</HEADING>
<P>None of these potential side effects were reported, but the authors speculate that the increased case-fatality rate in the intraventricular antibiotics group could be related to the procedure or to a direct toxic effect of gentamicin. See also information under "All-cause mortality during the hospital stay" above.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intraventricular antibiotics alone versus intravenous antibiotics alone</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Infants with or without a CSF shunt</HEADING>
<P>No eligible studies were found that allowed us to undertake either of these planned comparisons.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Planned subgroup analyses</HEADING>
<P>None of the planned subgroup analyses (by gestational age or birth weight classes, presence or absence of ventriculitis, type of organism or antibiotic used) could be conducted, because of lack of eligible data.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-05-28 12:51:25 -0400" MODIFIED_BY="[Empty name]">
<P>In this review we could compare intraventricular antibiotics plus intravenous antibiotics with intravenous antibiotics alone only in infants with confirmed ventriculitis/meningitis due to gram-negative organisms. This is likely to be the population that most justifies the intervention that was studied. In theory, the intraventricular route of administration of antibiotics would achieve higher antibiotic concentrations in the CSF and eliminate the bacteria more quickly.</P>
<P>Only one randomised or quasi-randomised trial related to this topic could be identified. The updated literature searches in June 2007 and May 2011 did not identify any additional studies for inclusion. The included study did not strictly fulfil all our selection criteria as the study included both neonates (69% of the infants were &#8804; 29 days old) and older infants (31%). As the majority of infants enrolled were neonates we considered it appropriate to report on the results of this study. The randomised controlled study design included concealed allocation to the two interventions, thus avoiding a major threat to validity. It is unclear if the outcomes were assessed blinded to group. This is more of a concern regarding the long-term follow-up assessments among survivors than all-cause mortality, which is an undisputable outcome. The study authors do not provide enough information to draw any conclusion regarding long-term developmental outcomes (age at assessment; incidence and degree of motor, cognitive and sensory impairments). No imaging techniques were applied to ascertain any damage caused by the intraventricular taps.</P>
<P>There was no statistically significant reduction in the duration of culture positivity of CSF, the major underlying rationale for intraventricular antibiotics in infants with meningitis/ventriculitis.</P>
<P>With the markedly increased mortality in the group receiving intraventricular plus intravenous antibiotics compared to the group receiving intravenous antibiotics group alone, further trials in neonates are not justified. The increased mortality could be related to the procedure itself or to toxicity of the intraventricularly administered gentamicin (<LINK REF="STD-McCracken-1980" TYPE="STUDY">McCracken 1980</LINK>). The increased mortality in the intraventricular antibiotics group is the likely reason why no further trials have been conducted.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-05-28 12:51:40 -0400" MODIFIED_BY="Anne Lawson">
<IMPLICATIONS_PRACTICE MODIFIED="2012-05-28 12:51:40 -0400" MODIFIED_BY="Anne Lawson">
<P>In infants with meningitis and ventriculitis, intraventricular antibiotics in combination with intravenous antibiotics resulted in a three-fold increased RR for mortality compared to standard treatment with intravenous antibiotics alone and should be avoided. These conclusions are based on one trial that enrolled infants with gram-negative meningitis and ventriculitis.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-05-28 12:51:40 -0400" MODIFIED_BY="Anne Lawson">
<P>Further trials comparing intraventricular plus intravenous antibiotics to intravenous antibiotics alone are not justified in this population.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank Dr. George H. McCracken Jr for answering questions related to the included trial. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="Anne Lawson">
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-06-06 10:54:30 -0400" MODIFIED_BY="[Empty name]">
<P>All review authors contributed to all stages of the protocol and the full review. The update of the review was conducted by Arne Ohlsson (AO) and Vibhuti Shah (VS).</P>
<P>The May 2011 update was conducted centrally by the Cochrane Neonatal Review Group staff (Yolanda Montagne, Diane Haughton and Roger Soll). <BR/>Although no new trials were identified for this update in 2011, AO and SS identified one retrospective study of interest to this review (<LINK REF="REF-Arnell-2007" TYPE="REFERENCE">Arnell 2007</LINK>) and included this information in the review. This update was reviewed and approved by Sachin Shah, Arne Ohlsson, and Vibhuti Shah. <BR/>&gt;<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-06-04 12:20:53 -0400" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-05-28 12:52:33 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-05-28 12:52:33 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-McCracken-1980" MODIFIED="2012-05-28 12:52:33 -0400" MODIFIED_BY="[Empty name]" NAME="McCracken 1980" YEAR="1980">
<REFERENCE MODIFIED="2012-05-28 12:52:33 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McCracken GH, Mize SG, Threlkeld N</AU>
<TI>Intraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy</TI>
<SO>Lancet</SO>
<YR>1980</YR>
<VL>1</VL>
<PG>787-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mustafa MM, Mertsola J, Ramilo O, Saez-Llorens X, Risser RC, McCracken GH</AU>
<TI>Increased endotoxin and interleukin1-beta concentrations in cerebrospinal fluid of infants with coliform meningitis and ventriculitis associated with intraventricular gentamicin therapy</TI>
<SO>The Journal of Infectious Diseases</SO>
<YR>1989</YR>
<VL>160</VL>
<PG>891-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-06-04 12:20:53 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-06-04 12:20:53 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Anderson-1990" NAME="Anderson 1990" TYPE="JOURNAL_ARTICLE">
<AU>Anderson SG, Gilbert GL</AU>
<TI>Neonatal gram negative meningitis: a 10-year review, with reference to outcome and relapse of infection</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>1990</YR>
<VL>26</VL>
<PG>212-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arnell-2007" MODIFIED="2011-07-26 10:32:22 -0400" MODIFIED_BY="[Empty name]" NAME="Arnell 2007" TYPE="JOURNAL_ARTICLE">
<AU>Arnell K, Enblad P, Wester T, Sjolin J</AU>
<TI>Treatment of cerebrospinal fluid shunt infections in children using systemic and intraventricular antibiotic therapy in combination with externalization of the ventricular catheter: efficacy in 34 consecutively treated infections</TI>
<SO>Journal of Neurosurgery</SO>
<YR>2007</YR>
<VL>107</VL>
<PG>213-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baumgartner-1983" NAME="Baumgartner 1983" TYPE="JOURNAL_ARTICLE">
<AU>Baumgartner ET, Augustine RA, Steele RW</AU>
<TI>Bacterial meningitis in older neonates</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1983</YR>
<VL>137</VL>
<PG>1052-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bell-1989" NAME="Bell 1989" TYPE="JOURNAL_ARTICLE">
<AU>Bell AH, Brown D, Halliday HL, McClure G, McReid M</AU>
<TI>Meningitis in the newborn - a 14 year review</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1989</YR>
<VL>64</VL>
<PG>873-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dawson-1999" NAME="Dawson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Dawson KG, Emerson JC, Burns JL</AU>
<TI>Fifteen years of experience with bacterial meningitis</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1999</YR>
<VL>18</VL>
<PG>816-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Flexner-1913" NAME="Flexner 1913" TYPE="JOURNAL_ARTICLE">
<AU>Flexner S</AU>
<TI>The results of serum treatment in thirteen hundred cases of epidemic meningitis</TI>
<SO>Journal of Experimental Medicine</SO>
<YR>1913</YR>
<VL>17</VL>
<PG>553-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Franco-1992" NAME="Franco 1992" TYPE="JOURNAL_ARTICLE">
<AU>Franco SM, Cornelius VE, Andrews BF</AU>
<TI>Long-term outcome of neonatal meningitis</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1992</YR>
<VL>146</VL>
<PG>567-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harvey-1999" NAME="Harvey 1999" TYPE="JOURNAL_ARTICLE">
<AU>Harvey D, Holt DE, Bedford H</AU>
<TI>Bacterial meningitis in the newborn: a prospective study of mortality and morbidity</TI>
<SO>Seminars in Perinatology</SO>
<YR>1999</YR>
<VL>23</VL>
<PG>218-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heath-2003" NAME="Heath 2003" TYPE="JOURNAL_ARTICLE">
<AU>Heath PT, Yusoff NK, Baker CJ</AU>
<TI>Neonatal meningitis</TI>
<SO>Archives of Disease in Childhood Fetal Neonatal Edition</SO>
<YR>2003</YR>
<VL>88</VL>
<PG>F173-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-05-28 12:53:24 -0400" MODIFIED_BY="Anne Lawson" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hristeva-1993" NAME="Hristeva 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hristeva L, Booy R, Bowler I, Wilkinson AR</AU>
<TI>Prospective surveillance of neonatal meningitis</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1993</YR>
<VL>69</VL>
<PG>14-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-James-1980" NAME="James 1980" TYPE="JOURNAL_ARTICLE">
<AU>James HE, Wlash JW, Wilson HD, Connor JD, Bean JR, Tibbs PA</AU>
<TI>Prospective randomized study of therapy in cerebrospinal fluid shunt infection</TI>
<SO>Neurosurgery</SO>
<YR>1980</YR>
<VL>7</VL>
<PG>459-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klein-2000" NAME="Klein 2000" TYPE="BOOK_SECTION">
<AU>Klein JO</AU>
<TI>Bacterial meningitis and sepsis</TI>
<SO>Remington JS, Klein JO (eds) Infectious diseases of the fetus and newborn infant</SO>
<YR>2000</YR>
<PG>943-98</PG>
<PB>WB Saunders</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klinger-2000" NAME="Klinger 2000" TYPE="JOURNAL_ARTICLE">
<AU>Klinger G, Chin CN, Beyene J, Perlman M</AU>
<TI>Predicting the outcome of neonatal bacterial meningitis</TI>
<SO>Pediatrics</SO>
<YR>2000</YR>
<VL>106</VL>
<PG>477-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-1977" NAME="Lee 1977" TYPE="JOURNAL_ARTICLE">
<AU>Lee EL, Robinson MJ, Thong ML, Puthucheary SD, Ong TH, Ng KK</AU>
<TI>Intraventricular chemotherapy in neonatal meningitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1977</YR>
<VL>91</VL>
<PG>991-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCracken-1972" NAME="McCracken 1972" TYPE="JOURNAL_ARTICLE">
<AU>McCracken GH</AU>
<TI>The rate of bacteriologic response to antimicrobial therapy in neonatal meningitis</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1972</YR>
<VL>123</VL>
<PG>547-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCracken-1982" NAME="McCracken 1982" TYPE="JOURNAL_ARTICLE">
<AU>McCracken GH, Nelson JD, Grimm L</AU>
<TI>Pharmacokinetics and bacteriological efficacy of cefoperazone, ceftriaxone, and moxalactam in experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1982</YR>
<VL>21</VL>
<PG>262-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Polin-2001" NAME="Polin 2001" TYPE="JOURNAL_ARTICLE">
<AU>Polin RA, Harris MC</AU>
<TI>Neonatal bacterial meningitis</TI>
<SO>Seminars in Neonatology</SO>
<YR>2001</YR>
<VL>6</VL>
<PG>157-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pong-1999" NAME="Pong 1999" TYPE="JOURNAL_ARTICLE">
<AU>Pong A, Bradley JS</AU>
<TI>Bacterial meningitis and the newborn infant</TI>
<SO>Infectious Disease Clinics of North America</SO>
<YR>1999</YR>
<VL>13</VL>
<PG>711-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quagliarello-1997" NAME="Quagliarello 1997" TYPE="JOURNAL_ARTICLE">
<AU>Quagliarello VJ, Scheld WM</AU>
<TI>Treatment of bacterial meningitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>336</VL>
<PG>708-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2012-05-28 12:53:44 -0400" MODIFIED_BY="Anne Lawson" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ronan-1995" NAME="Ronan 1995" TYPE="JOURNAL_ARTICLE">
<AU>Ronan A, Hogg GG, Klug GL</AU>
<TI>Cerebrospinal fluid shunt infections in children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1995</YR>
<VL>14</VL>
<PG>782-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salmon-1967" NAME="Salmon 1967" TYPE="JOURNAL_ARTICLE">
<AU>Salmon JH</AU>
<TI>Puncture porencephaly. Pathogenesis and prevention</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1967</YR>
<VL>114</VL>
<PG>72-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scheld-1984" NAME="Scheld 1984" TYPE="JOURNAL_ARTICLE">
<AU>Scheld WM, Mandell GL</AU>
<TI>Landmark perspective. Sulfonamides and meningitis</TI>
<SO>JAMA</SO>
<YR>1984</YR>
<VL>251</VL>
<PG>791-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stamos-1993" NAME="Stamos 1993" TYPE="JOURNAL_ARTICLE">
<AU>Stamos JK, Kaufman BA, Yogev R</AU>
<TI>Ventriculoperitoneal shunt infections with gram-negative bacteria</TI>
<SO>Neurosurgery</SO>
<YR>1993</YR>
<VL>33</VL>
<PG>858-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Unhanand--1993" NAME="Unhanand  1993" TYPE="JOURNAL_ARTICLE">
<AU>Unhanand M, Mustafa MM, McCracken GH, Nelson JD</AU>
<TI>Gram-negative enteric bacillary meningitis: a twenty-one-year experience</TI>
<SO>Journal of Pediatrics</SO>
<YR>1993</YR>
<VL>122</VL>
<PG>15-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Watanabe-1978" NAME="Watanabe 1978" TYPE="JOURNAL_ARTICLE">
<AU>Watanabe I, Hodges GR, Dworzack DL, Kepes JJ, Duensing GF</AU>
<TI>Neurotoxicity of intrathecal gentamicin: a case report and experimental study</TI>
<SO>Annals of Neurology</SO>
<YR>1978</YR>
<VL>4</VL>
<PG>564-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitehead-2001" NAME="Whitehead 2001" TYPE="JOURNAL_ARTICLE">
<AU>Whitehead WE, Kestle JR</AU>
<TI>The treatment of cerebrospinal fluid shunts. Results from a practice survey of the American Society of Pediatric Neurosurgeons</TI>
<SO>Pediatric Neurosurgery</SO>
<YR>2001</YR>
<VL>35</VL>
<PG>205-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wright-1981" NAME="Wright 1981" TYPE="JOURNAL_ARTICLE">
<AU>Wright PF, Kaiser AB, Bowman CM, McKee KT Jr, Trujillo H, McGee ZA</AU>
<TI>The pharmacokinetics and efficacy of an aminoglycoside administered into the cerebral ventricles in neonates: implications for further evaluation of this route of therapy in meningitis</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1981</YR>
<VL>143</VL>
<PG>141-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-06-13 09:39:31 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Shah-2004" MODIFIED="2011-06-13 09:39:31 -0400" MODIFIED_BY="[Empty name]" NAME="Shah 2004" TYPE="COCHRANE_REVIEW">
<AU>Shah S, Ohlsson A, Shah V</AU>
<TI>Intraventricular antibiotics for bacterial meningitis in neonates</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-06-13 09:39:31 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-06-13 09:39:31 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004496.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCracken-1980">
<CHAR_METHODS MODIFIED="2012-05-28 12:51:50 -0400" MODIFIED_BY="[Empty name]">
<P>Multicentre (20 institutions in the US and Latin America) randomised controlled trial<BR/>Recruitment dates March 1976 to December 1979<BR/>Blinding of randomisation - yes (sealed numbered envelopes)<BR/>Blinding of intervention - no<BR/>Blinding of outcome measure assessment - cannot determine<BR/>Completeness of follow-up - yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<P>87 infants were considered for enrolment<BR/>16 infants were found to be unacceptable for the following reasons: (1) CSF cultures from 6 infants were sterile or yielded non-enteric organisms; (2) the pathogens from 4 patients were known to be resistant in vitro to ampicillin and gentamicin before enrolment; (3) 2 infants died before treatment was started; (4) 2 infants' physicians would not allow their patients to be enrolled; (5) in 1 infant ventriculitis could not be distinguished from intraventricular haemorrhage and (6) 1 infant with Down's syndrome was excluded because of the difficulty in evaluating neurological and mental status after therapy<BR/>The remaining 71 infants comprised the study population<BR/>52 infants (73%) had meningitis and ventriculitis at the time of enrolment and 19 infants (27%) did not have ventriculitis<BR/>16 of the 52 infants with ventriculitis were &#8805; to 30 days old (31%). Thus 69% of the infants were 29 days or younger (close to the conventional definition of a neonate, i.e. &lt; 28 days of age)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-28 12:52:02 -0400" MODIFIED_BY="[Empty name]">
<P>Intraventricular antibiotics (n = 28): gentamicin 2.5 mg/day intraventricularly for a minimum of 3 days<BR/>No intraventricular antibiotics (n = 24): no intraventricular drug or placebo<BR/>All infants in both groups received systemic antibiotics: for those &#8804; 7 days, ampicillin 50 mg/kg q12h IV and gentamicin 2.5 mg/kg q12h IM or IV, for those &gt; 7 days, ampicillin 70 mg/kg q8h IV and gentamicin 2.5 mg/kg q8h IM or IV</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-28 12:52:07 -0400" MODIFIED_BY="Anne Lawson">
<P>Mortality<BR/>Days positive CSF cultures<BR/>Long-term follow-up</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-28 12:52:12 -0400" MODIFIED_BY="Anne Lawson">
<P>19 infants had meningitis without ventriculitis. 9 of these were assigned to lumbar intrathecal gentamicin plus systemic antibiotics, and 10 to systemic antibiotics only. These 2 groups were not included in this review because intraventricular antibiotics were not tested in these infants</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CSF: cerebrospinal fluid; IM: intramuscular; IV: intravenous; q8h: quaque 8 hora (every 8 hours); q12h: quaque 12 hora (every 12 hours).</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-05-28 12:52:15 -0400" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-04-29 17:05:58 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-29 17:05:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCracken-1980">
<DESCRIPTION>
<P>Tables of random permutations of 16 numbers for each institution</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-04-29 17:06:19 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-29 17:06:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCracken-1980">
<DESCRIPTION>
<P>Yes (sealed numbered envelopes)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-04-30 11:49:18 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-30 11:49:18 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McCracken-1980">
<DESCRIPTION>
<P>The intervention could not be blinded<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-05-28 12:52:15 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-28 12:52:15 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCracken-1980">
<DESCRIPTION>
<P>Completeness of follow-up - yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-04-30 11:49:33 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-30 11:49:33 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McCracken-1980">
<DESCRIPTION>
<P>The protocol for the study was not available to us</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-04-30 11:49:39 -0400" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-30 11:49:39 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCracken-1980">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-04-26 09:10:11 -0400" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-04-26 09:10:11 -0400" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-05-28 12:54:16 -0400" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-05-28 12:54:16 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Intraventricular antibiotics for meningitis in infants receiving intravenous antibiotics</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.737992494599187" CI_START="1.0947206423108145" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.4285714285714284" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.0309230960739226" LOG_CI_START="0.039303307320775804" LOG_EFFECT_SIZE="0.5351132016973491" METHOD="MH" MODIFIED="2012-05-28 12:54:16 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.034401649353730045" Q="0.0" RANDOM="NO" SCALE="10.84" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="24" WEIGHT="100.0" Z="2.1153321361153483">
<NAME>All-cause mortality during hospital stay</NAME>
<GROUP_LABEL_1>Intraventricular</GROUP_LABEL_1>
<GROUP_LABEL_2>No intraventricular</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No intravent</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.737992494599187" CI_START="1.0947206423108147" EFFECT_SIZE="3.4285714285714284" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="1.0309230960739226" LOG_CI_START="0.03930330732077589" LOG_EFFECT_SIZE="0.5351132016973491" ORDER="1" O_E="0.0" SE="0.5824823725107174" STUDY_ID="STD-McCracken-1980" TOTAL_1="28" TOTAL_2="24" VAR="0.33928571428571425" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="8.76590036026549E-32" CI_END="0.2699076548203323" CI_START="-2.6699076548203333" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2000000000000004" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2012-05-14 12:12:08 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.10958280783312975" Q="0.0" RANDOM="NO" SCALE="2.68" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="1.6000711158522039">
<NAME>Duration of culture positivity of CSF (days)</NAME>
<GROUP_LABEL_1>Intraventricular</GROUP_LABEL_1>
<GROUP_LABEL_2>No intraventricular</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No intravent</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.2699076548203325" CI_START="-2.669907654820333" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="4.2" ORDER="2" SD_1="2.38" SD_2="2.94" SE="0.7499666659258929" STUDY_ID="STD-McCracken-1980" TOTAL_1="28" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-06-04 12:22:09 -0400" MODIFIED_BY="[Empty name]">Search Strategy - May 2011</TITLE>
<APPENDIX_BODY MODIFIED="2012-05-28 12:54:43 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">PubMed</HEADING>
<P>(meningitis AND intraventricular AND antibiotics) AND ((infant, newborn[MeSH] OR newborn OR neon* OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW) AND (randomised controlled trial [pt] OR controlled clinical trial [pt] OR randomised [tiab] OR placebo [tiab] OR clinical trials as topic [mesh: noexp] OR randomly [tiab] OR trial [ti]) NOT (animals [mh] NOT humans [mh])) AND (("2006"[PDat] : "3000"[PDat]))</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE</HEADING>
<P>1 (infant, newborn or newborn or neonate or neonatal or premature or very low birth weight or low birth weight or VLBW or LBW).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (607975)</P>
<P>2 (human not animal).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (11910500)</P>
<P>3 (randomized controlled trial or controlled clinical trial or randomized or placebo or clinical trials as topic or randomly or trial or clinical trial).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (1266847)</P>
<P>4 meningitis/ or meningitis.mp. (59009)</P>
<P>5 intraventricular antibiotics.mp. (28)</P>
<P>6 antibiotic agent/ (151738)</P>
<P>7 5 or 6 (151751)</P>
<P>8 1 and 2 and 3 and 4 and 7 (55)</P>
<P>9 limit 8 to yr="2007 -Current" (23)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">CINAHL</HEADING>
<P>(meningitis AND intraventricular antibiotics) and ((infant, newborn OR newborn OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW) AND (randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR clinical trials as topic OR randomly OR trial OR PT clinical trial)) </P>
<P>Limiters - published date from: 1 January 2007 to present</P>
<P>the Cochrane Central Register of Controlled Trials</P>
<P>(infant or newborn or neonate or neonatal or premature or very low birth weight or low birth weight or VLBW or LBW) and meningitis and "intraventricular antibiotics" from 2007 to 2011</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Clinicaltrials.gov</HEADING>
<P>Searched: (infant OR newborn) AND meningitis AND antibiotics</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Controlled-trials.com</HEADING>
<P>Searched: (infant OR newborn) AND meningitis AND antibiotics</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>